WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Sarcoidosis Vasc Diffuse Lung Dis · 2025 · PMC12536850 · PMID 41026013

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

barely significantno p-value reported

By contrast, threshold analyses of change in FVC of 10% of predicted normal were non-significant in one trial (p=0.18) and only barely significant in the other.

also in 875 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.